Skip to main content
. Author manuscript; available in PMC: 2024 Jul 8.
Published in final edited form as: Int J Hyperthermia. 2020 Jul;37(2):27–34. doi: 10.1080/02656736.2020.1746413

Table 3.

Extracranial hyperthermia (HT) with immunotherapy (IT) clinical trials.

Clinical trial indicator HT method IT agent Population Phase Status
NCT03757858 RFA ACT, ACT plus pembrolizumab, ACT plus standard CT, or standard CT Adults with abdominal or pelvic malignancies or metastases I/II Recruiting
NCT03393858 RFA ACT and pembrolizumab Adults with advanced malignant mesothelioma I/II Recruiting

ACT: adoptive T cell therapy; CT: chemotherapy; RFA: radiofrequency ablation.